APM
BIO icon

Avidity Partners Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Avidity Partners Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-152,600
Closed -$57.9M – 89
2023
Q2 		$57.9M Sell
152,600
-68,900
-31% -$28M 2.02% 16
2023
Q1 		$106M Buy
221,500
+129,300
+140% +$60.5M 3.52% 3
2022
Q4 		$38.8M Sell
92,200
-52,600
-36% -$21.2M 0.84% 38
2022
Q3 		$60.4M Buy
+144,800
New +$72.2M 1.23% 29

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Avidity Partners Management's BIO Position: Q3 2023 in Review

Avidity Partners Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2023, closing a stake of 152,600 shares — an estimated $57.9M sold.

Avidity Partners Management first reported a position in BIO in Q3 2022 and held it in 4 quarters. The position peaked at $106M in Q1 2023. 468 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

  • Avidity Partners Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2023 after selling out during the quarter.
  • Avidity Partners Management sold 152,600 Bio-Rad Laboratories Class A shares in Q3 2023, an estimated $57.9M.
  • Avidity Partners Management first reported a position in Bio-Rad Laboratories Class A in Q3 2022 and held it in 4 quarters.
  • Avidity Partners Management's Bio-Rad Laboratories Class A position peaked at $106M in Q1 2023.
  • 468 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on Avidity Partners Management's 13F filing for Q3 2023, filed 14 Nov 2023.